Results 141 to 150 of about 200,531 (312)

Atopic eczema [PDF]

, 2007
A distressed mother attends the clinic with her three year old daughter, who developed an itchy rash. The rash is reddish and affects her face and wrists. The child is restless and has been scratching all night.
Formosa, Marie Claire
core  

Engineering Lipid Nanoparticles for Precision RNA Delivery: Design Principles, Targeting Strategies, and Clinical Prospects

Cancer Nexus, EarlyView.
ABSTRACT Lipid nanoparticles (LNPs) represent the most clinically advanced platform for RNA delivery and have enabled major breakthroughs in vaccines and gene therapies. However, their broader application is still limited by inefficient extrahepatic delivery, immunogenicity, and insufficient control over tissue‐ and cell‐specific targeting. This review
Yu Han, Ying Wang, Xintao Gao, Yan Lei, Yantao Li, Zhiyong Tang   +5 more
wiley   +1 more source

Asthma severity: the patient’s point of view

European Clinical Respiratory Journal
Objective Initiated by the Severe Asthma Network Italy (SANI), this study aims to explore asthma patients’ perceptions of disease severity, differentiating between mild and severe asthma.
Gabriella Guarnieri, Bianca Olivieri, Manuela Latorre, Angela Rizzi, Francesco Blasi, Giorgio Walter Canonica, Enrico Heffler, Pierluigi Paggiaro, Gianenrico Senna, Marco Caminati   +9 more
doaj   +1 more source

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

Clinical Pharmacology &Therapeutics, EarlyView.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld, Geetha S. Iyer, Suna C. Seo, Andrew Giffin, Andrew L. Simon, Sheryl A. Kluberg, Emma R. Hoffman, Jamal T. Jones, Sarah K. Dutcher, Joyce A. Korvick   +9 more
wiley   +1 more source

Clinical remission and control in severe asthma: agreements and disagreements

Drugs in Context
Over the last two decades, we have witnessed great advancements in our understanding of the immunological pathways of asthma, leading to the development of targeted therapies, such as biologic drugs, that have radically and definitively changed the ...
Annamaria Bosi, Carlo Lombardi, Cristiano Caruso, Marcello Cottini, Ilaria Baglivo, Stefania Colantuono, Francesco Menzella   +6 more
doaj   +1 more source

Prevalence and prescribing patterns of oral corticosteroids in the United States, Taiwan, and Denmark, 2009-2018. [PDF]

Clin Transl Sci, 2023
Wallace BI, Tsai HJ, Lin P, Aasbjerg K, Wu AC, Tsai YF, Torp-Pedersen C, Waljee AK, Yao TC.   +8 more
europepmc   +1 more source

Association of Neurodevelopmental Disorders and Congenital Anomalies With Prenatal Multiple Sclerosis Treatment—Real‐World Historical Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
There is a paucity of data regarding the effects of prenatal disease‐modifying therapies (DMTs) for multiple sclerosis (MS), on congenital anomalies in the offspring. Moreover, data on the association with neurodevelopmental disorders are lacking. This is an historical cohort study, within the Israeli Clalit Health Services database (2005–2024) that ...
Bar Rosh, Ofek Levi, Nili Stein, Amir Yahav, Naomi Gronich   +4 more
wiley   +1 more source

Prospective REALITI-A StudyTake-home Points

CHEST Pulmonary
Background: Mepolizumab, a monoclonal antibody targeting IL-5, is of proven clinical benefit in severe asthma; however, prospective, long-term, real-world data in severe asthma are required. Research Question: What is the real-world benefit of 2 years of
Cristiano Caruso, MD, PhD, G. Walter Canonica, MD, Manish Patel, MBChB, PhD, Andrew Smith, MBChB, PhD, Mark C. Liu, MD, Rafael Alfonso-Cristancho, MD, PhD, Robert G. Price, MSc, Rupert W. Jakes, PhD, Lydia Demetriou, MSc, Antonio Valero, MD, Thomas C. Köhler, MD, Charles Pilette, MD, PhD, Geoffrey Chupp, MD, Guy Brusselle, MD, Peter Howarth, DM   +14 more
doaj   +1 more source

A Charter to Fundamentally Change the Role of Oral Corticosteroids in the Management of Asthma. [PDF]

Adv Ther, 2023
Haughney J, Winders T, Holmes S, Chanez P, Menzies-Gow A, Kocks J, Mansur AH, McPherson C, Canonica GW.   +8 more
europepmc   +1 more source

Implementation of OMOP and ConcePTION Common Data Models in CPRD GOLD: Risk of Bleeding and Cardiovascular Outcomes From Anticoagulant Use

Clinical Pharmacology &Therapeutics, EarlyView.
The impact of the choice of common data model (CDM) approach on the study results in a real‐world evidence (RWE) study is unknown. We aimed to determine potential differences in the results of an RWE study when data were mapped to two different CDMs, ConcePTION and OMOP. With the same instance of CPRD GOLD, data were mapped to both CDMs. Using the same
Nicholas B. Hunt, Patrick Souverein, Marloes Bazelier, Nicola Barclay, Antonella Delmestri, Miriam Sturkenboom, Daniel Prieto‐Alhambra, Helga Gardarsdottir, Olaf Klungel   +8 more
wiley   +1 more source